Please login to the form below

Not currently logged in

Aurobindo joins Patent Pool

Aurobindo Pharma has become the first generics manufacturer to join the Medicines Patent Pool for the manufacture of HIV/AIDS treatments

Aurobindo Pharma has become the first generics manufacturer to join the Medicines Patent Pool for the manufacture of HIV/AIDS treatments.

The agreement will enable Aurobindo to manufacture products licensed to the Pool by Gilead Sciences in July: emtricitabine, cobicistat, elvitegravir, and the fixed-dose combination of these medicines known as the Quad (a combination of the three drugs and tenofovir).

The Pool said generic manufacturers choosing to develop and manufacture these treatments will help close the gap between the arrival of new medical technology in developed country markets and its often delayed arrival in developing countries.

Aurobindo has chosen not to take a licence on tenofovir, on which there is currently no product patent in India, meaning the company does not have to pay royalties on the product.

The Medicines Patent Pool, founded with the support of UNITAID in 2010, aims to bring down the prices of HIV medicines, and stimulate the development of needed new formulations, through access-oriented voluntary licences.

The Pool's voluntary licences are negotiated to maximise their public health impact.

PV Ramaprasad Reddy, chairman of Aurobindo, said: "We are excited about both the public health and business opportunities provided by the Patent Pool licences. Aurobindo looks forward to increasing its manufacture of HIV-related products, and expanding its work to cover promising new treatments, for the millions of people living with HIV across the globe."

12th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...